{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T02:49:26Z","timestamp":1777949366594,"version":"3.51.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Medical research Fund of Shenzhen Medical Academy of Research and Translation","award":["C2301004"],"award-info":[{"award-number":["C2301004"]}]},{"name":"Science, Technology & Innovation Commission of Shenzhen Municipality","award":["JCYJ20230807112359022"],"award-info":[{"award-number":["JCYJ20230807112359022"]}]},{"name":"Shenzhen Fund for Guangdong Provincial High-level Clinical Key Specialties","award":["SZGSP001"],"award-info":[{"award-number":["SZGSP001"]}]},{"name":"Shenzhen key Laboratory of Kidney Diseases","award":["SYSPG20241211173908024"],"award-info":[{"award-number":["SYSPG20241211173908024"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-026-04859-4","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T15:39:58Z","timestamp":1774366798000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A systematic review and meta-analysis of mesenchymal stem cell therapy in diabetic nephropathy and lupus nephritis or proteinuric nephropathy"],"prefix":"10.1186","volume":"27","author":[{"given":"Jingyi","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hualin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumeng","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiantao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"4859_CR1","unstructured":"CKDWG, Kidney Disease: Improving Global Outcomes. Kidney Int. 2024;105(4S):S117\u2013314. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease."},{"key":"4859_CR2","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1159\/000496533","volume":"198","author":"Y Takemoto","year":"2019","unstructured":"Takemoto Y, Naganuma T. Economic Issues of Chronic Kidney Disease and End-Stage Renal Disease. Contrib Nephrol. 2019;198:87\u201393.","journal-title":"Contrib Nephrol"},{"issue":"15","key":"4859_CR3","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"issue":"2","key":"4859_CR4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"E-KCG The","year":"2023","unstructured":"The E-KCG, et al. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023;388(2):117\u201327.","journal-title":"N Engl J Med"},{"key":"4859_CR5","doi-asserted-by":"publisher","first-page":"15018","DOI":"10.1038\/nrdp.2015.18","volume":"1","author":"MC Thomas","year":"2015","unstructured":"Thomas MC, et al. Diabetic kidney disease. Nat Rev Dis Primers. 2015;1:15018.","journal-title":"Nat Rev Dis Primers"},{"key":"4859_CR6","doi-asserted-by":"crossref","unstructured":"Swamy S, Noor SM, Mathew RO. Cardiovascular disease in diabetes and chronic kidney disease. J Clin Med. 2023;12(22).","DOI":"10.3390\/jcm12226984"},{"issue":"2","key":"4859_CR7","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1681\/ASN.2012070718","volume":"24","author":"M Afkarian","year":"2013","unstructured":"Afkarian M, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013;24(2):302\u20138.","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"4859_CR8","doi-asserted-by":"publisher","first-page":"902","DOI":"10.3899\/jrheum.2024-1087","volume":"52","author":"K Cohen-Hagai","year":"2025","unstructured":"Cohen-Hagai K, et al. Risk Factors, and Outcomes of Chronic Kidney Disease in Patients With Systemic Lupus Erythematosus With and Without Lupus Nephritis. J Rheumatol. 2025;52(9):902\u20138.","journal-title":"J Rheumatol"},{"key":"4859_CR9","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes Lupus Nephritis Work, G., KDIGO 2024 Clinical Practice Guideline for the management of Lupus Nephritis. Kidney Int. 2024;105(1S): pp. S1-S69.","DOI":"10.1016\/j.kint.2023.09.002"},{"issue":"2","key":"4859_CR10","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/ehjcvp\/pvad001","volume":"9","author":"G Filippatos","year":"2023","unstructured":"Filippatos G, et al. Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis. Eur Heart J Cardiovasc Pharmacother. 2023;9(2):183\u201391.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"4859_CR11","doi-asserted-by":"publisher","first-page":"1384454","DOI":"10.3389\/fmed.2024.1384454","volume":"11","author":"M Arici","year":"2024","unstructured":"Arici M, et al. The significance of finerenone as a novel therapeutic option in diabetic kidney disease: a scoping review with emphasis on cardiorenal outcomes of the finerenone phase 3 trials. Front Med (Lausanne). 2024;11:1384454.","journal-title":"Front Med (Lausanne)"},{"key":"4859_CR12","doi-asserted-by":"publisher","first-page":"637725","DOI":"10.3389\/fcell.2021.637725","volume":"9","author":"L Muller","year":"2021","unstructured":"Muller L, et al. Immunomodulatory Properties of Mesenchymal Stromal Cells: An Update. Front Cell Dev Biol. 2021;9:637725.","journal-title":"Front Cell Dev Biol"},{"issue":"8","key":"4859_CR13","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41581-022-00586-9","volume":"18","author":"C Grange","year":"2022","unstructured":"Grange C, Bussolati B. Extracellular vesicles in kidney disease. Nat Rev Nephrol. 2022;18(8):499\u2013513.","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"4859_CR14","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1186\/s12951-024-02852-3","volume":"22","author":"B Li","year":"2024","unstructured":"Li B, et al. Frontier role of extracellular vesicles in kidney disease. J Nanobiotechnol. 2024;22(1):583.","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"4859_CR15","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1186\/s13287-017-0742-8","volume":"8","author":"AK Berglund","year":"2017","unstructured":"Berglund AK, et al. Immunoprivileged no more: measuring the immunogenicity of allogeneic adult mesenchymal stem cells. Stem Cell Res Ther. 2017;8(1):288.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"4859_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cei.12929","volume":"188","author":"F Carty","year":"2017","unstructured":"Carty F, Mahon BP, English K. The influence of macrophages on mesenchymal stromal cell therapy: passive or aggressive agents? Clin Exp Immunol. 2017;188(1):1\u201311.","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"4859_CR17","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1186\/s13287-021-02609-x","volume":"12","author":"Y Wang","year":"2021","unstructured":"Wang Y, Yi H, Song Y. The safety of MSC therapy over the past 15 years: a meta-analysis. Stem Cell Res Ther. 2021;12(1):545.","journal-title":"Stem Cell Res Ther"},{"issue":"10","key":"4859_CR18","doi-asserted-by":"publisher","first-page":"e47559","DOI":"10.1371\/journal.pone.0047559","volume":"7","author":"MM Lalu","year":"2012","unstructured":"Lalu MM, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS ONE. 2012;7(10):e47559.","journal-title":"PLoS ONE"},{"key":"4859_CR19","doi-asserted-by":"publisher","first-page":"891514","DOI":"10.3389\/fneur.2022.891514","volume":"13","author":"CE Kvistad","year":"2022","unstructured":"Kvistad CE, et al. Safety and Clinical Efficacy of Mesenchymal Stem Cell Treatment in Traumatic Spinal Cord Injury, Multiple Sclerosis and Ischemic Stroke - A Systematic Review and Meta-Analysis. Front Neurol. 2022;13:891514.","journal-title":"Front Neurol"},{"key":"4859_CR20","doi-asserted-by":"publisher","first-page":"100249","DOI":"10.1016\/j.eclinm.2019.100249","volume":"19","author":"M Thompson","year":"2020","unstructured":"Thompson M, et al. Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: An updated systematic review and meta-analysis. EClinicalMedicine. 2020;19:100249.","journal-title":"EClinicalMedicine"},{"issue":"18","key":"4859_CR21","doi-asserted-by":"publisher","first-page":"30511","DOI":"10.18632\/oncotarget.15426","volume":"8","author":"R Zhao","year":"2017","unstructured":"Zhao R, et al. Serious adverse events of cell therapy for respiratory diseases: a systematic review and meta-analysis. Oncotarget. 2017;8(18):30511\u201323.","journal-title":"Oncotarget"},{"key":"4859_CR22","doi-asserted-by":"publisher","first-page":"100438","DOI":"10.1016\/j.lanepe.2022.100438","volume":"20","author":"J Sundstrom","year":"2022","unstructured":"Sundstrom J, et al. Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2.4 million patients from 11 countries: The CaReMe CKD study. Lancet Reg Health Eur. 2022;20:100438.","journal-title":"Lancet Reg Health Eur"},{"key":"4859_CR23","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ebiom.2016.09.011","volume":"12","author":"DK Packham","year":"2016","unstructured":"Packham DK, et al. Allogeneic Mesenchymal Precursor Cells (MPC) in Diabetic Nephropathy: A Randomized, Placebo-controlled. Dose Escalation Study EBioMedicine. 2016;12:263\u20139.","journal-title":"Dose Escalation Study EBioMedicine"},{"issue":"10","key":"4859_CR24","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1681\/ASN.0000000000000189","volume":"34","author":"N Perico","year":"2023","unstructured":"Perico N, et al. Safety and Preliminary Efficacy of Mesenchymal Stromal Cell (ORBCEL-M) Therapy in Diabetic Kidney Disease: A Randomized Clinical Trial (NEPHSTROM). J Am Soc Nephrol. 2023;34(10):1733\u201351.","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"4859_CR25","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1136\/annrheumdis-2017-211073","volume":"76","author":"D Deng","year":"2017","unstructured":"Deng D, et al. A randomised double-blind, placebo-controlled trial of allogeneic umbilical cord-derived mesenchymal stem cell for lupus nephritis. Ann Rheum Dis. 2017;76(8):1436\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"4859_CR26","doi-asserted-by":"publisher","first-page":"R79","DOI":"10.1186\/ar4520","volume":"16","author":"D Wang","year":"2014","unstructured":"Wang D, et al. Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study. Arthritis Res Ther. 2014;16(2):R79.","journal-title":"Arthritis Res Ther"},{"issue":"13","key":"4859_CR27","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1177\/0961203318804922","volume":"27","author":"J Barbado","year":"2018","unstructured":"Barbado J, et al. Therapeutic potential of allogeneic mesenchymal stromal cells transplantation for lupus nephritis. Lupus. 2018;27(13):2161\u20135.","journal-title":"Lupus"},{"issue":"5","key":"4859_CR28","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.jcyt.2018.02.368","volume":"20","author":"A Makhlough","year":"2018","unstructured":"Makhlough A, et al. Bone marrow-mesenchymal stromal cell infusion in patients with chronic kidney disease: A safety study with 18 months of follow-up. Cytotherapy. 2018;20(5):660\u20139.","journal-title":"Cytotherapy"},{"key":"4859_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2019.03.016","volume":"285","author":"AS Moghaddam","year":"2019","unstructured":"Moghaddam AS, et al. Cardioprotective microRNAs: Lessons from stem cell-derived exosomal microRNAs to treat cardiovascular disease. Atherosclerosis. 2019;285:1\u20139.","journal-title":"Atherosclerosis"},{"issue":"1","key":"4859_CR30","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12882-025-04029-y","volume":"26","author":"J Li","year":"2025","unstructured":"Li J, Wu M, He L. Immunomodulatory effects of mesenchymal stem cell therapy in chronic kidney disease: a literature review. BMC Nephrol. 2025;26(1):107.","journal-title":"BMC Nephrol"},{"issue":"1\u20132","key":"4859_CR31","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.biopha.2004.06.003","volume":"59","author":"M Camici","year":"2005","unstructured":"Camici M. Renal glomerular permselectivity and vascular endothelium. Biomed Pharmacother. 2005;59(1\u20132):30\u20137.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"4859_CR32","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/MNM.0000000000001128","volume":"41","author":"M Oliveira-Santos","year":"2020","unstructured":"Oliveira-Santos M, et al. Renal artery wall 18F-NaF activity and glomerular filtration rate: an exploratory analysis in a high cardiovascular risk population. Nucl Med Commun. 2020;41(2):126\u201332.","journal-title":"Nucl Med Commun"},{"issue":"6","key":"4859_CR33","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1681\/ASN.0000000000000117","volume":"34","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink HJL, et al. Change in Albuminuria and GFR Slope as Joint Surrogate End Points for Kidney Failure: Implications for Phase 2 Clinical Trials in CKD. J Am Soc Nephrol. 2023;34(6):955\u201368.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"4859_CR34","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41591-025-04057-z","volume":"32","author":"HJL Heerspink","year":"2025","unstructured":"Heerspink HJL, et al. A meta-analysis of albuminuria as a surrogate endpoint for kidney failure. Nat Med. 2025;32(1):281\u20137.","journal-title":"Nat Med"},{"issue":"1","key":"4859_CR35","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1186\/s13063-021-05574-1","volume":"22","author":"N Evangelidis","year":"2021","unstructured":"Evangelidis N, et al. Standardised Outcomes in Nephrology - Chronic Kidney Disease (SONG-CKD): a protocol for establishing a core outcome set for adults with chronic kidney disease who do not require kidney replacement therapy. Trials. 2021;22(1):612.","journal-title":"Trials"},{"issue":"6","key":"4859_CR36","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.kint.2018.08.018","volume":"94","author":"A Tong","year":"2018","unstructured":"Tong A, et al. Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology (SONG) implementation workshop. Kidney Int. 2018;94(6):1053\u201368.","journal-title":"Kidney Int"},{"issue":"11","key":"4859_CR37","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/ni.3002","volume":"15","author":"Y Wang","year":"2014","unstructured":"Wang Y, et al. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat Immunol. 2014;15(11):1009\u201316.","journal-title":"Nat Immunol"},{"issue":"11","key":"4859_CR38","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1002\/stem.217","volume":"27","author":"L Zangi","year":"2009","unstructured":"Zangi L, et al. Direct imaging of immune rejection and memory induction by allogeneic mesenchymal stromal cells. Stem Cells. 2009;27(11):2865\u201374.","journal-title":"Stem Cells"},{"issue":"6","key":"4859_CR39","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1182\/blood-2005-11-011650","volume":"108","author":"AJ Nauta","year":"2006","unstructured":"Nauta AJ, et al. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood. 2006;108(6):2114\u201320.","journal-title":"Blood"},{"issue":"8","key":"4859_CR40","doi-asserted-by":"publisher","first-page":"e6657","DOI":"10.1371\/journal.pone.0006657","volume":"4","author":"RM Baertschiger","year":"2009","unstructured":"Baertschiger RM, et al. Fibrogenic potential of human multipotent mesenchymal stromal cells in injured liver. PLoS ONE. 2009;4(8):e6657.","journal-title":"PLoS ONE"},{"issue":"1","key":"4859_CR41","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s40164-024-00532-4","volume":"13","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Wang C, Li JJ. Revisiting the role of mesenchymal stromal cells in cancer initiation, metastasis and immunosuppression. Exp Hematol Oncol. 2024;13(1):64.","journal-title":"Exp Hematol Oncol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-04859-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04859-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04859-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T23:27:16Z","timestamp":1777850836000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-04859-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4859"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-04859-4","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"26 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"279"}}